<DOC>
	<DOCNO>NCT01514448</DOCNO>
	<brief_summary>Patients metastatic renal cell carcinoma ( mRCC ) fail first-line therapy sunitinib pazopanib treat everolimus . Efficacy safety everolimus evaluate thesis patient .</brief_summary>
	<brief_title>Safety Efficacy Everolimus Metastatic Renal Cell Carcinoma After Failure First Line Therapy With Sunitinib Pazopanib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients advance renal cell carcinoma histological cytological confirmation clear cell renal carcinoma . Progression treatment sunitinib pazopanib give 1st line treatment situation mRCC . Patients schedule treatment everolimus . Patients least one measurable lesion baseline . Patients receive &gt; 1 prior systemic treatment metastatic RCC . Prior systemic treatment adjuvant setting allow . Patients previously receive systemic mTOR inhibitor ( e.g . sirolimus , temsirolimus , everolimus ) . Patients use investigational agent receive investigational drug â‰¤ 2 week prior study treatment start . Patients unwilling unable comply protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>mRCC</keyword>
	<keyword>metastic renal cell carcinoma</keyword>
	<keyword>everolimus</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pazopanib</keyword>
</DOC>